BPA Call 36E79719A0032-36C26222N0412
Award Date 3/16/22
Potential Completion Date 9/30/22
Potential Value $281K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This delivery order, awarded under the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19, is for the purchase of pegolticase 8mg/ml injection 1ml single dose vials from Horizon Therapeutics USA Inc. The $16,558.72 firm fixed price contract has a completion date of June 20, 2022 and was awarded on May 18, 2022. The contract calls for the delivery of pegolticase, a drug used to treat...
- This delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 to Horizon Therapeutics USA Inc. for the provision of pegolticase, a drug used to treat gout, with a potential value of $16,558.72. The order has a firm fixed price and period of performance through March 31, 2022 to support the VA's healthcare programs serving veterans in the Lake...
- Horizon Therapeutics USA Inc. has been awarded a $14,785.51 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6. The firm fixed price order is for the delivery of 8mg/ml peglicotase injection solution to the Richmond, VA area by March 10, 2021. No set-aside designation was applied to this order placed under GSA Schedule contract FSS-61-IB. The delivery supports...
- Horizon Therapeutics USA Inc. was awarded a $0.00 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 23. The firm fixed price order is for the delivery of Peglicotase 8mg/ml injection solution to a location in Lake Forest, Illinois. The completion date is September 30, 2022. No set-aside designation was used for this order to supply pharmaceutical products through...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $198,704.64 delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The firm fixed price order is for the purchase of PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10, with a completion date of November 30, 2022. The contract has no set-aside designation and calls for the delivery of pharmaceutical products to...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $430,526.72 delivery order contract to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. Horizon Therapeutics will provide Pegloticase (Krystexxa), a medication used to treat chronic gout refractory to conventional therapy, to the Puget Sound VA Medical Center located in Seattle, Washington. Performance will take place from...
- This delivery order for $33,117.44 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The order is for an emergency request of Pegloticase (Krystexxa) medication for a patient with chronic gout at the Veterans Affairs San Diego Healthcare System, with performance at the facility in Dublin, Ohio. No set-aside...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order for KRYSTEXXA 8MG to the prime contractor, Horizon Therapeutics USA, Inc. This order, valued at $74,537.76, was placed against Horizon's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The delivery order has an April 17, 2024 completion date and will provide the specialized orphan drug to VHA hospitals and clinics across the country...
- Horizon Therapeutics USA Inc. was awarded a $39,411.69 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22. The firm fixed price order is for the delivery of pegloticase (Krystexxa) to a location in Lake Forest, Illinois, with performance to be completed by July 31, 2020. No set-aside designation was applied to this order placed under the GSA Schedule...
- The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a delivery order to Horizon Therapeutics USA Inc. for KRYSTEXXA 8MG, a specialty pharmaceutical product. The order, valued at $55,903.32, was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and did not have a set-aside designation. Horizon Therapeutics is a global biotechnology company that provides orphan drugs and specialty pharmaceuticals to support...